famotidine has been researched along with Aggressive Systemic Mastocytosis in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Aggressive Systemic Mastocytosis: A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolck, UW | 1 |
| Alfter, K | 1 |
| Homann, J | 1 |
| von Kügelgen, I | 1 |
| Molderings, GJ | 1 |
1 other study available for famotidine and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
Cardiac mast cells: implications for heart failure.
Topics: Chronic Disease; Famotidine; Female; Heart Failure; Humans; Male; Mast Cells; Mastocytosis, Systemic | 2007 |